The epigenetics of ovarian cancer drug resistance and resensitization.
about
Overexpression of Cancer-Associated Genes via Epigenetic Derepression Mechanisms in Gynecologic CancerA Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to TumorigenesisEnriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cellsSeparate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell lineModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesComparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancerEpigenetic therapies for chemoresensitization of epithelial ovarian cancer.The biology of ovarian cancer: new opportunities for translationDNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review)A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancerSecreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancersPhase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerPotential markers for detection and monitoring of ovarian cancer.Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxelEpigenomics and ovarian carcinoma.TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.SGI-110: DNA Methyltransferase Inhibitor OncolyticTangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway.Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancerOverexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathwaysEpigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines.Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expressionDNMT1, DNMT3A and DNMT3B gene variants in relation to ovarian cancer risk in the Polish populationNF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.Minireview: epigenetic changes in ovarian cancer.Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cellsMECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effect.RETRACTED: Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis.HtrA serine proteases as potential therapeutic targets in cancer.Role of epigenomics in ovarian and endometrial cancers.Recent advances in drug delivery strategies for treatment of ovarian cancer.Cancer development, progression, and therapy: an epigenetic overview.Epigenetics and oncology.The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance.Promoter demethylation of nuclear factor-erythroid 2-related factor 2 gene in drug-resistant colon cancer cells.Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
P2860
Q21129296-2F229DBC-D040-4CC3-8289-A2539967AEC3Q26746952-E1502142-9FA2-4955-A64E-B72596B4DA9CQ28390582-835233AF-F40D-4EC4-811D-D57761C0911BQ28538117-F7491CEB-76FB-4208-86E2-8EA94DA457B6Q30570945-7BBD31C8-19CD-496B-9F73-9905ECDD413BQ33249818-F4D055BF-C9A3-4059-A532-BF9219925534Q33463860-82048119-900D-43F1-892D-E29BE059038EQ33621141-5C6801BD-0F84-4804-A74B-390894D20719Q33622369-E1B39D0C-E233-49C5-B800-E9413FA278A2Q33799002-DF2C9177-4776-4C93-947D-538256193E6AQ34091420-4A5E59EE-274E-452B-9A7C-0ED71CB33062Q34435134-6105976A-F6BA-4A3F-AA37-77574C6DBC0CQ34711457-714A0CB0-705D-4737-B7C0-14DA720B186FQ34960174-F60E8C56-61BF-40AD-812F-32154DCDBFEDQ35169206-676F371C-5CEE-4CCE-973D-5D6AC2C37378Q35184495-C734650C-EB3B-489A-A1D8-1303E21DD3EEQ35636575-6AA43FDA-0E72-4FAE-ADDA-5734DDDCEF8CQ35768799-50BEBF80-A128-46AC-9E7F-8EF474E095ADQ35854709-53C8935E-5257-4CF3-B031-8EDBFDB531DEQ35869232-EAD4E805-FC3E-4B43-8D10-18BC678565AAQ36067023-C4FD4651-A4A3-43A3-B7D6-D2DC2916117BQ36492785-B564AF31-F8BE-4B08-8632-838169F2F618Q36614480-1C4E4922-8FFA-4918-9236-A2898716D367Q36700778-670C420C-F8BD-4EC7-AD5A-43B2DE646806Q37000936-09523623-F47F-4182-88AB-B2DA1CA5604DQ37022528-345EA9E2-8562-4327-A0B9-DD8C14079067Q37046397-90653DC3-AA5D-4447-ABF7-A75758134946Q37309839-F4F64E56-D991-47A1-BD50-FF8EFBB516ECQ37328836-E48A9960-2B54-4726-A866-137BDF02C1D3Q37332214-7DAFE83C-0058-4574-90CE-4C1CA878AF58Q37376407-CE2C643A-6BA4-4F94-B2E5-84DA1F640BEDQ37479727-AAF186D6-6A1D-4206-BBF2-17A5C9582E95Q37515512-1E06163D-4B61-4183-9311-BA179266CE67Q37961734-70B53040-C016-4191-AFEA-A7A31A836C2CQ37997512-F5678F96-AACD-41CD-9482-5C69290CAE56Q38154977-106A9933-436A-41F3-8084-F8F6EA27F059Q38195260-02724A8B-B646-454F-B0A4-DA42C59FE4DDQ38748127-1E4B0734-3E21-4C19-BBFA-40E527775C8DQ38815478-7F3C7219-F546-474A-B66C-D82ABF9C62E8Q39220493-87050260-5B6C-4C6E-B622-4CDD3462C213
P2860
The epigenetics of ovarian cancer drug resistance and resensitization.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The epigenetics of ovarian cancer drug resistance and resensitization.
@ast
The epigenetics of ovarian cancer drug resistance and resensitization.
@en
type
label
The epigenetics of ovarian cancer drug resistance and resensitization.
@ast
The epigenetics of ovarian cancer drug resistance and resensitization.
@en
prefLabel
The epigenetics of ovarian cancer drug resistance and resensitization.
@ast
The epigenetics of ovarian cancer drug resistance and resensitization.
@en
P2093
P1476
The epigenetics of ovarian cancer drug resistance and resensitization.
@en
P2093
Curtis Balch
Kenneth P Nephew
Robert Brown
Tim H-M Huang
P304
P356
10.1016/J.AJOG.2004.05.025
P407
P577
2004-11-01T00:00:00Z